Chugai Pharmaceutical (OTCMKTS:CHGCY) Raised to “Strong-Buy” at Smbc Nikko Sec.

Chugai Pharmaceutical (OTCMKTS:CHGCY) was upgraded by equities research analysts at Smbc Nikko Sec. to a “strong-buy” rating in a report issued on Wednesday,Zacks.com reports.

Separately, UBS Group raised Chugai Pharmaceutical to a “strong-buy” rating in a report on Tuesday, January 27th. Two equities research analysts have rated the stock with a Strong Buy rating, According to MarketBeat, the stock currently has a consensus rating of “Strong Buy”.

Chugai Pharmaceutical Stock Performance

OTCMKTS:CHGCY opened at $33.00 on Wednesday. The stock has a market capitalization of $108.60 billion, a PE ratio of 37.93 and a beta of 0.63. Chugai Pharmaceutical has a fifty-two week low of $19.50 and a fifty-two week high of $34.50. The company has a fifty day moving average of $28.15 and a two-hundred day moving average of $25.32.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last released its earnings results on Thursday, January 29th. The company reported $0.25 EPS for the quarter. The business had revenue of $2.25 billion during the quarter. Chugai Pharmaceutical had a net margin of 34.47% and a return on equity of 22.00%. Research analysts forecast that Chugai Pharmaceutical will post 0.74 earnings per share for the current year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.